Zhang, Yu
Vu, Trang
Palmer, Douglas C.
Kishton, Rigel J.
Gong, Lanqi
Huang, Jiao http://orcid.org/0000-0002-6275-0451
Nguyen, Thanh
Chen, Zuojia
Smith, Cari
Livák, Ferenc
Paul, Rohit
Day, Chi-Ping http://orcid.org/0000-0001-5200-2372
Wu, Chuan
Merlino, Glenn http://orcid.org/0000-0001-8610-0616
Aldape, Kenneth http://orcid.org/0000-0001-5119-7550
Guan, Xin-yuan http://orcid.org/0000-0002-4485-6017
Jiang, Peng http://orcid.org/0000-0002-7828-5486
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (Intramural Research Budget)
Article History
Received: 30 June 2021
Accepted: 24 March 2022
First Online: 2 May 2022
Change Date: 11 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-022-01997-8
Competing interests
: NCI, NIH has submitted a provisional patent application no. 63/246,743 for using <i>FIBP</i> KO to enhance cellular immunotherapy efficacies, with P.J. and Y.Z. as inventors. All other authors declare no competing interests.